Begrundelsen for artikel 30- indbringelsen af Roaccutan var, at Roaccutan som følge af divergerende nationale afgørelser ikke har samme produktresumé i alle medlemsstater.
The rationale for the article 30 referral of Roaccutane was due to the fact that Roaccutane does not have the same summary of product characteristics across Member States due to divergent national decisions.